The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials to evaluate weekly doses of up to 10 mg of ribupatide (KAI-9531) administered by subcutaneous injection over 76 weeks:

    • KaiNETIC-1 (NCT07284875): enrolled approximately 2,500 adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with a comorbidity, excluding type 2 diabetes.
    • KaiNETIC-2 (NCT07284901): enrolled approximately 1,200 adults with a BMI of 27 kg/m2 or greater with type 2 diabetes.
    • KaiNETIC-3 (NCT07284979): enrolled approximately 1,200 adults with a BMI of 35 kg/m2 or greater and without type 2 diabetes. This trial will include an arm that will be randomized to open-label semaglutide 2.4 mg subcutaneous weekly injection.

Learn more at kaineticstudies.com.